ResMed presents plan for annual gross margin gains through 2030
RMD•ResMed reported 7% Q1 FY27 core constant-currency revenue growth and a target of annual gross margin gains of double-digit basis points through 2030. Non-GAAP earnings per share rose 14%, and non-GAAP operating margin was 35.8%.
1. Results and margin target
ResMed reported Q1 FY27 core constant-currency revenue growth of 7% in its company overview presentation. Non-GAAP earnings per share rose 14%, non-GAAP operating margin reached 35.8%, and trailing 12-month revenue totaled $5.7 billion, with free cash flow of $1.6 billion. Gross margin exceeded expectations, benefiting from the timing of supply-chain expansion investments. Its operational improvement pipeline targets annual gross margin gains of double-digit basis points through 2030.




